Compounds > uric acid
Page last updated: 2024-10-20

uric acid and Chronic Progressive Multiple Sclerosis

uric acid has been researched along with Chronic Progressive Multiple Sclerosis in 3 studies

Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.

Research Excerpts

ExcerptRelevanceReference
"Uric acid (UA) has been suggested to be a marker of multiple sclerosis (MS) activity."7.79Long-term effects of whole body cryostimulation on uric acid concentration in plasma of secondary progressive multiple sclerosis patients. ( Miller, E; Morel, A; Saluk, J; Wachowicz, B, 2013)
"Uric acid (UA) has been suggested to be a marker of multiple sclerosis (MS) activity."3.79Long-term effects of whole body cryostimulation on uric acid concentration in plasma of secondary progressive multiple sclerosis patients. ( Miller, E; Morel, A; Saluk, J; Wachowicz, B, 2013)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Miller, E2
Saluk, J2
Morel, A1
Wachowicz, B1
Walczak, A1
Ponczek, MB1
Majsterek, I1
Spitsin, S1
Hooper, DC1
Leist, T1
Streletz, LJ1
Mikheeva, T1
Koprowskil, H1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Treatment of Multiple Sclerosis Using Over the Counter Inosine[NCT00067327]Phase 230 participants Interventional2002-02-28Completed
A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effects of Food on the Pharmacokinetics of Urate After a Single Dose of Inosine in Healthy Male Subjects[NCT02614469]Phase 118 participants (Actual)Interventional2015-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

AUC (0-inf): Area Under the Serum Concentration-time Curve From Time 0 to Infinity

(NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Interventionmg*hr/dL (Mean)
Inosine Fed2040
Inosine Fasted2031

AUC (0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t (Time of Last Quantifiable Plasma Concentration)

(NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Interventionmg*hr/dL (Mean)
Inosine Fed267
Inosine Fasted268

Baseline Corrected AUC (0-inf): Baseline Corrected Area Under the Serum Concentration-time Curve From Time 0 to Infinity

Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, and 48 hrs post-dose

Interventionmg*hr/dL (Mean)
Inosine Fed80.4
Inosine Fasted83.0

Baseline Corrected AUC (0-t): Baseline Corrected Area Under the Serum Concentration-time Curve From Time 0 to Time t (Time of Last Quantifiable Serum Concentration)

Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). Negative concentrations were set to zero. (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Interventionmg*hr/dL (Mean)
Inosine Fed36.1
Inosine Fasted39.3

Baseline Corrected Cmax: Baseline Corrected Maximum Serum Concentration

Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). Negative concentrations were set to zero. (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Interventionmg/dL (Mean)
Inosine Fed1.73
Inosine Fasted1.65

Baseline Corrected T1/2: Baseline Corrected Apparent Terminal Half-life

Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Interventionhr (Mean)
Inosine Fed44.3
Inosine Fasted44.7

Baseline Corrected Tmax: Baseline Corrected Time of Maximum Serum Concentration

Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). (NCT02614469)
Timeframe: -12 to 0 h pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, and 48 hrs post-dose

Interventionhr (Median)
Inosine Fed3.0
Inosine Fasted3.0

Cmax: Maximum Observed Serum Urate Concentration

(NCT02614469)
Timeframe: -12 to 0 hrs pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hrs post-dose

Interventionmg/dL (Mean)
Inosine Fed6.6
Inosine Fasted6.4

Safety Assessment (Vital Signs)

Number of participants with clinically significant findings in vital signs by investigator after study drug administration. (NCT02614469)
Timeframe: Up to 10 days after first study drug administration at Day 1 of Period 1

Interventionparticipants (Number)
Inosine Fed0
Inosine Fasted0

Safety Assessment: Adverse Events

Number of participants with adverse events after study drug administration (NCT02614469)
Timeframe: Up to 10 days after first study drug administration at Day 1 of Period 1

Interventionparticipants (Number)
Inosine Fed0
Inosine Fasted0

T1/2: Apparent Terminal Half-life

(NCT02614469)
Timeframe: -12 to 0 pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Interventionhr (Mean)
Inosine Fed242
Inosine Fasted241

Tmax: Time of Maximum Serum Concentration

(NCT02614469)
Timeframe: -12 to 0 hr pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Interventionhr (Median)
Inosine Fed3.0
Inosine Fasted3.0

Trials

1 trial available for uric acid and Chronic Progressive Multiple Sclerosis

ArticleYear
Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2001, Volume: 7, Issue:5

    Topics: Administration, Oral; Adult; Female; Gadolinium; Humans; Inosine; Magnetic Resonance Imaging; Male;

2001
Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2001, Volume: 7, Issue:5

    Topics: Administration, Oral; Adult; Female; Gadolinium; Humans; Inosine; Magnetic Resonance Imaging; Male;

2001
Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2001, Volume: 7, Issue:5

    Topics: Administration, Oral; Adult; Female; Gadolinium; Humans; Inosine; Magnetic Resonance Imaging; Male;

2001
Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2001, Volume: 7, Issue:5

    Topics: Administration, Oral; Adult; Female; Gadolinium; Humans; Inosine; Magnetic Resonance Imaging; Male;

2001

Other Studies

2 other studies available for uric acid and Chronic Progressive Multiple Sclerosis

ArticleYear
Long-term effects of whole body cryostimulation on uric acid concentration in plasma of secondary progressive multiple sclerosis patients.
    Scandinavian journal of clinical and laboratory investigation, 2013, Volume: 73, Issue:8

    Topics: Adult; Biomarkers; Cryotherapy; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Multiple Scle

2013
Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis.
    Clinical biochemistry, 2012, Volume: 45, Issue:1-2

    Topics: Adult; Blood Proteins; Blood-Brain Barrier; Carbon; Disease Progression; Female; Humans; Male; Middl

2012